Mayne Pharma Group Ltd. MYX
ASX · Australia · Health Technology
AUD 2.850.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Mayne Pharma navigates a challenging year with a 411 bps gross margin improvement, driven by DistributeRx momentum and key product wins, despite a 27% drop in underlying EBITDA.
Marquis Who's Who honors Shawn Patrick O'Brien for his expertise in pharmaceuticals and biotechnology. Mr. O'Brien is a seasoned professional in the pharmaceutical industry with over four decades of experience.
It’s looking like we could be in for a green finish to the week with ASX futures tipping a rise of 0.5% for the ASX pre-market after oil prices dipped again overnight and gold travelled back above US$4,500 an ounce. While 'penny stocks' might seem like an outdated term, they continue to offer intriguing possibilities for investors seeking affordable entry points and growth potential. In this article, we highlight three penny stocks that showcase financial strength and resilience, offering...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.